Codexis (Nasdaq:CDXS) - Stock Analysis
This analysis of Codexis (Nasdaq:CDXS) highlights its stock performance, market capitalization, and financial health. While the company operates in a volatile market, analysts project significant earnings growth. The article also details recent news, price history, and key initiatives like the ECO platform aimed at transforming pharma manufacturing.
Q3 2025 Codexis Inc Earnings Call Transcript
This article provides the Q3 2025 earnings call transcript for Codexis Inc, detailing both positive and negative developments. The company signed a supply assurance agreement with Merck, expanded its contract base, and is transitioning into a full-service manufacturing innovator. However, it also reported a decrease in total revenues, an increase in R&D expenses, a net loss, and is undergoing restructuring with headcount reductions.
Vanguard disaggregates holdings; Codexis Inc (NASDAQ: CDXS) shows 0 shares
The Vanguard Group filed an amended Schedule 13G/A for Codexis Inc (NASDAQ: CDXS), reporting zero beneficially owned shares. This change stems from an internal realignment on January 12, 2026, where certain Vanguard subsidiaries or business divisions began reporting their holdings separately. Vanguard and its affiliates now collectively hold less than 5% of Codexis's class of securities.
Analyst Sentiment Unchanged After Codexis (CDXS) Earnings
Codexis, Inc. (CDXS) recently announced its Q4 2025 earnings, reporting strong revenue growth and improved gross margins. Despite a low price target from TD Cowen, the company's CodeEvolver platform and 2026 growth plans, focused on new contracts and licensing, highlight its potential in the enzyme discovery and manufacturing sectors. Analyst sentiment has remained largely unchanged post-earnings.
Benchmark reiterates Hold on Codexis stock after Q4 results
Benchmark has reiterated a Hold rating on Codexis (NASDAQ:CDXS) following its Q4 2025 financial results, where the company reported revenues of $38.9 million and a net income of $9.6 million, boosted by a technology transfer agreement with Merck. Despite a quarterly profit, the company remains unprofitable over the last twelve months. Codexis provided 2026 revenue guidance of $72 million to $76 million and is transitioning to new product lines.
Biocatalysis Market Accelerates with Rising Demand in Pharmaceuticals, Food Processing, and Biofuels | Top Companies are Biocatalysts Limited, Novozymes A/S, Codexis, Inc
The global Biocatalysis Market is experiencing rapid growth, projected to reach USD 908 million by 2031 with a CAGR of 5.2%. This expansion is driven by increasing demand for sustainable chemical processes in pharmaceuticals, food processing, and biofuels, alongside advancements in enzyme engineering and stringent environmental regulations. Key players like Biocatalysts Limited, Novozymes A/S, and Codexis, Inc. are innovating with next-generation enzymes and AI-assisted platforms.
Biocatalysis and Biocatalysts Market is expected to Hit US$ 6.7 billion by 2032 | Major Companies - Novozymes A/S, Dupont, BASF SE, Codexis Inc.
The global Biocatalysis and Biocatalysts Market is projected to reach US$ 6.7 billion by 2032, growing at a CAGR of 9.2% from 2025-2032, up from US$ 3.0 billion in 2023. This growth is driven by the increasing demand for sustainable and eco-friendly production processes in pharmaceuticals, food & beverages, biofuels, and chemical manufacturing. The market focuses on using natural catalysts like enzymes and microorganisms to accelerate chemical reactions, with key players including Novozymes A/S, Dupont, and BASF SE.
Short Interest in Codexis, Inc. (NASDAQ:CDXS) Grows By 26.2%
Short interest in Codexis, Inc. (NASDAQ:CDXS) surged by 26.2% to 9,161,843 shares as of February 27th, representing 10.3% of shares outstanding and an 8.5-day days-to-cover ratio. Despite beating Q4 revenue and EPS estimates, the company remains unprofitable with a "Hold" average analyst rating and a $5.00 price target. Several institutional investors have adjusted their holdings in CDXS.
Codexis (NASDAQ:CDXS) Upgraded to "Hold" at Wall Street Zen
Wall Street Zen has upgraded Codexis (NASDAQ:CDXS) from a "strong sell" to a "hold" rating, contributing to a consensus "Hold" rating among analysts with a $5.00 price target, despite mixed individual ratings. The company recently surpassed quarterly earnings and revenue expectations but remains unprofitable, with institutional investors holding a significant portion of its stock. Codexis, a protein engineering company, specializes in developing enzyme solutions for various industrial applications using its proprietary CodeEvolver® platform.
Codexis (CDXS) Q4 Profit Turns Positive EPS Into Test Of Turnaround Narrative
Codexis (CDXS) reported a positive Q4 2025 with $38.9 million in revenue and a basic EPS of $0.11, marking a significant shift from trailing twelve-month losses. While this profitability sparks optimism among investors, the company still faces ongoing TTM losses and a short cash runway, testing the sustainability of its turnaround narrative. Analysts maintain mixed views, with bulls highlighting the potential of ECO Synthesis and enzyme partnerships, while bears emphasize the historical losses and need for additional funding.
Cantor Fitzgerald Maintains Overweight on Codexis (CDXS) March 2026
Cantor Fitzgerald reaffirmed its "Overweight" rating on Codexis (CDXS) on March 12, 2026, following the company's Q4 results, indicating continued confidence in its commercial recovery and long-term growth. The firm did not issue a new price target, suggesting they maintain prior valuation assumptions and are awaiting further commercial milestones. Meyka AI also rates CDXS with a "B" grade, advising investors to watch for concrete commercial milestones and confirmed CDMO deals.
Why Did Codexis (CDXS) Stock Soar Nearly 38% After Hours?
Codexis (CDXS) stock surged nearly 38% after hours following a strong fourth-quarter and full-year 2025 earnings report. The company reversed a net loss to achieve a $9.6 million profit in Q4 and exceeded analyst revenue estimates, driving investor optimism despite past performance challenges. Codexis also provided a positive 2026 revenue outlook and expects to fund operations through 2027, with plans for a pharmaceutical licensing deal.
Codexis (CDXS) Stock Jumps 2.4% Following Strong Q4 Earnings Report
Codexis (CDXS) saw its stock jump 2.4% after reporting Q4 2025 earnings that significantly surpassed analyst expectations, with EPS of $0.11 against a forecasted $0.01 and revenue up 81% year-over-year to $38.9 million. The company's strong performance was largely driven by a $37.8 million Technology Transfer Agreement with Merck, leading to an improved annual net loss and a positive net income for Q4. Codexis projects 2026 revenue between $72 million and $76 million and confirms sufficient cash reserves through 2027.
Codexis: Q4 Earnings Snapshot
Codexis Inc. (CDXS) reported fourth-quarter earnings of $9.6 million, or 11 cents per share, surpassing analyst revenue forecasts with $38.9 million. Despite a full-year loss of $44 million, the company projects 2026 full-year revenue to be between $72 million and $76 million. This financial update was generated using data from Zacks Investment Research.
Codexis (CDXS) Stock Rises 2.4% After Q4 Earnings Beat
Codexis (CDXS) reported strong Q4 and full-year 2025 results, beating analyst estimates for both earnings and revenue, which led to a 2.4% rise in its stock. The company's Q4 revenue surge was primarily driven by a $37.8 million Technology Transfer Agreement with Merck, significantly narrowing its net loss for the full year. Despite a positive earnings report and institutional buying, analyst sentiment remains bearish, with the stock trading closer to its 52-week low.
Codexis Shines as Q4 Profit Sparks Investor Enthusiasm
Codexis Inc. (NASDAQ: CDXS) shares have surged by 35.04% after the company reported a surprising Q4 profit of $0.11 EPS and strong revenue growth to $38.9M, significantly surpassing analyst predictions. This positive financial performance, coupled with a strategic partnership for siRNA production and optimistic revenue guidance of $72M-$76M for FY26, has boosted investor confidence and positioned the company for future growth amidst competitive pressures in the biotech sector. The market has reacted favorably, sending the stock price higher and highlighting increasing investor interest in Codexis's innovative technologies.
Stifel reiterates Codexis stock Buy rating on solid 2026 guidance
Stifel has reiterated a Buy rating and a $5.00 price target for Codexis, Inc. (NASDAQ:CDXS) after the company's 2025 results and positive 2026 guidance exceeded expectations. Analysts have revised earnings upwards, and while the stock is down 48% in six months, Stifel views it as an undervalued small-cap investment, citing its strong performance in emerging modality therapeutics and a successful Q4 2025 earnings report.
Codexis Inc reports results for the quarter ended December 31 - Earnings Summary
Codexis Inc has reported its earnings results for the quarter that ended on December 31. The summary of these results is available through TradingView News, sourced from Reuters. Further details can be accessed by logging in or creating a free account.
Codexis (CDXS) Surges on Strong Q4 2025 Results and Optimistic Outlook
Codexis (CDXS) reported strong Q4 2025 results, with an 81% year-over-year revenue increase to $38.9 million, largely due to a technology transfer agreement with Merck, and achieved a net income of $9.6 million. The company's 2026 revenue projections of $72 million to $76 million exceed consensus estimates, and it expects cash reserves to last through 2027. Despite these recent positive results, the company faces significant financial health challenges, including a negative three-year revenue growth rate, high debt, and an Altman Z-Score in the distress zone.
Codexis, Inc. (NASDAQ:CDXS) Q4 2025 Earnings Call Transcript
Codexis, Inc. (NASDAQ:CDXS) announced strong Q4 and full-year 2025 financial results, with a significant increase in revenue primarily driven by a technology transfer agreement with Merck. The company highlighted the successful development and commercialization efforts for its ECOsynthesis manufacturing platform, focusing on RNA medicine production, and outlined plans for continued growth and capital expenditures through 2027. Management provided guidance for 2026 revenue between $72 million and $76 million, emphasizing the disruptive potential of their technology in oligonucleotide manufacturing.
Codexis Reports Fourth Quarter and Fiscal Year 2025 Financial Results
Codexis, Inc. announced its financial results for the fourth quarter and fiscal year ended December 31, 2025, reporting a significant 81% increase in Q4 revenue to $38.9 million and a 19% increase in total fiscal year revenue to $70.4 million. The company highlighted major strides in its ECO Synthesis® Manufacturing Platform, securing multiple contracts and advancing its technology for oligonucleotide manufacturing, with a strong cash position of $78.2 million expected to fund operations through 2027. Codexis also provided 2026 financial guidance, projecting total revenues between $72 million and $76 million.
Codexis Reports Fourth Quarter and Fiscal Year 2025 Financial Results
Codexis, Inc. announced its financial results for the fourth quarter and fiscal year ended December 31, 2025, highlighting a Q4 revenue of $38.9 million and total fiscal year revenue of $70.4 million. The company ended the year with $78.2 million in cash, cash equivalents, and short-term investments, projecting a runway through 2027, and completed a significant $37.8 million Technology Transfer Agreement with Merck. Codexis also provided 2026 financial guidance, anticipating total revenues between $72 million and $76 million, and detailed business highlights and upcoming milestones related to its ECO Synthesis® Manufacturing Platform.
Codexis: Q4 Earnings Snapshot
Codexis Inc. (CDXS) reported fourth-quarter earnings of $9.6 million, or 11 cents per share, with revenue reaching $38.9 million, exceeding analyst expectations. For the full year, the company had a loss of $44 million on revenue of $70.4 million. Codexis anticipates full-year revenue to be between $72 million and $76 million.
Codexis: Q4 Earnings Snapshot
Codexis Inc. (CDXS) reported fourth-quarter earnings of $9.6 million, or 11 cents per share, with revenue of $38.9 million, exceeding analyst forecasts. Despite this, the company posted a full-year loss of $44 million, or 50 cents per share, on revenue of $70.4 million. Codexis projects full-year revenue for the upcoming period to be between $72 million and $76 million.
Laurence Lytton holds 4.53M shares at Codexis (NASDAQ: CDXS)
Laurence W. Lytton has reported a beneficial ownership of 4,532,069 shares of Common Stock in Codexis, Inc. (NASDAQ: CDXS), which represents a 5.0% stake. This disclosure, made via a Schedule 13G filing, indicates a passive investment with Lytton holding sole voting and dispositive power over these shares. The percentage is calculated based on 90,324,383 shares outstanding as of November 3, 2025.
Codexis signs deal to produce siRNA for pharma partner
Codexis Inc. has secured an agreement with a pharmaceutical company to produce 50 grams of small interfering RNA (siRNA) using its ECO Synthesis platform. This siRNA will support preclinical development for a cardiovascular therapeutic, demonstrating the platform's capability beyond early research volumes. The deal represents a significant growth opportunity for Codexis, whose shares are currently near their 52-week low but are considered undervalued by analysts.
Codexis Inc expected to post a loss of 4 cents a share - Earnings Preview
Codexis Inc (CDXS) is anticipated to report an earnings loss of 4 cents per share. This information comes from a Refinitiv earnings preview. The article provides financial news from Reuters concerning the company's upcoming earnings report.
Codexis, Inc. Hits New 52-Week Low at $0.96 Amid Financial Struggles
Codexis, Inc. has reached a new 52-week low of $0.96, marking a significant decline of 67.07% over the past year. The specialty chemicals company reported negative financial results for four consecutive quarters, including a 39.82% drop in net sales and a negative return on equity. These struggles, coupled with a market capitalization of $106 million and a negative debt-to-equity ratio, raise concerns about the company's long-term viability and growth prospects.
Biotech Codexis tapped to scale RNA ingredient for heart drug research
Codexis (NASDAQ: CDXS) has announced an agreement to manufacture 50 grams of small interfering RNA (siRNA) using its ECO Synthesis platform for a partner's preclinical cardiovascular program. This agreement demonstrates the platform's ability to produce material beyond early research volumes and serves as a potential pathway to further scale-up and commercial manufacturing. While no financial terms were disclosed, the deal highlights Codexis's ongoing efforts to commercialize its ECO Synthesis platform for larger-scale RNA therapeutics.
Why Did CDXS Stock Jump 7% Today?
Codexis, Inc. (CDXS) shares rose 7% after announcing an agreement with an innovator pharmaceutical company to manufacture small interfering RNA (siRNA) using its ECO Synthesis platform for a cardiovascular therapeutic candidate. This partnership, following an earlier evaluation agreement with Axolabs, signals significant potential for high-volume RNA manufacturing as demand increases. The company is also expected to report strong Q4 results next week, with projected revenue growth of 67%.
CDXS SEC Filings - Codexis Inc 10-K, 10-Q, 8-K Forms
This page provides a comprehensive resource for investors to access Codexis (CDXS) SEC filings, including annual 10-K, quarterly 10-Q, and material event 8-K reports, along with insider trading information. Stock Titan offers AI-powered summaries to help investors understand key aspects of these regulatory documents. Recent filings highlight financial results, a workforce reduction to refocus on the ECO Synthesis platform, and institutional ownership changes.
CDXS Financials: Income Statement, Balance Sheet & Cash Flow
This article provides a detailed financial overview of Codexis Inc (CDXS), including its income statement, balance sheet, cash flow statement, and key financial ratios. Based on FY2024 data, the company shows weak profitability with a negative operating margin and declining revenue, despite having low debt and comfortable liquidity. The analysis highlights an overall weak financial health score and low earnings quality, suggesting that earnings are driven more by accounting accruals than cash generation.
Codexis to Report Fourth Quarter and Fiscal Year 2025 Financial Results on March 11
Codexis, Inc. (NASDAQ: CDXS) announced it will release its financial results for the fourth quarter and fiscal year 2025 on Wednesday, March 11, 2026, after market close. Following the release, company management will host a conference call and webcast at 4:30 pm Eastern Time to discuss the results and provide a business update. The webcast will be available on the Codexis Investor Relations website, and a replay will be accessible for 48 hours.
[Form 4] CODEXIS, INC. Insider Trading Activity
CODEXIS, INC. CEO, Alison Moore, was granted a stock option for 993,000 shares on February 23, 2026, as per a Form 4 SEC filing. This derivative award vests over four years, with 25% vesting on the first anniversary and the remainder vesting monthly thereafter, contingent on her continued employment. The transaction is categorized as an acquisition and reflects a neutral sentiment regarding its impact on the company.
Codexis to Report Fourth Quarter and Fiscal Year 2025 Financial Results on March 11
Codexis, Inc. announced it will release its fourth quarter and fiscal year 2025 financial results on Wednesday, March 11, 2026, after the market closes. The company will host a conference call and webcast at 4:30 pm Eastern Time to discuss these results and provide a business update. Investors can access the webcast on the Codexis Investor Relations website or join the call by phone.
Codexis to Report Fourth Quarter and Fiscal Year 2025 Financial Results on March 11
Codexis, Inc. announced it will report its financial results for the fourth quarter and fiscal year 2025 on Wednesday, March 11, 2026, after the market closes. Management will host a conference call and webcast at 4:30 pm Eastern Time to discuss the results and provide a business update, which will be accessible via their investor relations website.
Codexis to Report Fourth Quarter and Fiscal Year 2025 Financial Results on March 11
Codexis, Inc. (NASDAQ: CDXS) announced it will report its fourth quarter and fiscal year 2025 financial results on Wednesday, March 11, 2026, after the market closes. The company will host a conference call and webcast at 4:30 pm Eastern Time to discuss the results and provide a business update. A replay of the call will be available for 48 hours following the event.
Codexis Inc expected to post a loss of 4 cents a share - Earnings Preview
Codexis Inc (CDXS) is anticipated to report a loss of 4 cents per share. This information comes from a Reuters earnings preview, highlighting the company's expected financial performance. The article is brief and focuses solely on this upcoming earnings estimate.
Codexis (CDXS) Projected to Post Earnings on Thursday
Codexis (NASDAQ:CDXS) is projected to announce its Q4 2025 earnings before market open on Thursday, February 26th, with analysts forecasting EPS of $0.01 and revenue of $35.834 million. The biotechnology company will host an earnings call on Friday, February 27th at 4:00 PM ET. CDXS shares opened at $1.17, with a market capitalization of $105.67 million, and currently hold a "Sell" rating from Wall Street analysts.
Codexis to Participate in TD Cowen 46th Annual Health Care Conference
Codexis, Inc. announced its participation in the TD Cowen 46th Annual Health Care Conference, scheduled for March 2-4, 2026, in Boston, Massachusetts. Management will host a fireside chat on March 3, 2026, at 11:50 am ET, with a live webcast and replay available on the company's investor relations website. Codexis develops enzymatic solutions for therapeutic manufacturing using its CodeEvolver® technology platform.
Codexis to Participate in TD Cowen 46th Annual Health Care Conference
Codexis, Inc. announced its participation in the TD Cowen 46th Annual Health Care Conference, scheduled for March 2-4, 2026, in Boston, Massachusetts. Management will engage in a fireside chat on March 3, 2026. A live webcast and archived replay will be available on the company's Investor Relations website.
Codexis to Participate in TD Cowen 46th Annual Health Care Conference
Codexis, Inc. (NASDAQ: CDXS) announced its participation in the TD Cowen 46th Annual Health Care Conference, scheduled for March 2-4, 2026. Management will host a fireside chat on March 3, 2026, at 11:50 am ET, with a live webcast available on the company's investor relations website. The company specializes in enzymatic solutions for manufacturing complex therapeutics and is developing its ECO Synthesis® platform for RNAi therapeutics.
Positive Sentiment Still Eludes Codexis, Inc. (NASDAQ:CDXS) Following 29% Share Price Slump
Codexis, Inc. (NASDAQ:CDXS) has seen its share price drop by 29% in the last month and 71% over the past year, leading to a low price-to-sales (P/S) ratio of 2x, which is lower than many peers in the Life Sciences industry. Despite recent revenue decline, analysts project strong future growth of 32% per year for the next three years, significantly outpacing the industry forecast of 7.7%. The low P/S ratio suggests investors might be skeptical of these growth forecasts or perceive underlying risks, even though price risks appear minimal.
Positive Sentiment Still Eludes Codexis, Inc. (NASDAQ:CDXS) Following 29% Share Price Slump
Codexis, Inc. (NASDAQ:CDXS) has experienced a 29% share price drop in the last month and a 71% decline over the past year, leading to a low price-to-sales (P/S) ratio of 2x. Despite its revenue decreasing by 18% in the last year, analysts forecast a 32% annual revenue growth for the next three years, significantly higher than the industry average. The low P/S ratio, despite strong growth forecasts, suggests investor skepticism regarding potential risks and future revenue volatility.
Codexis Achieves ISO 9001:2015 Certification
Codexis Inc. announced it has achieved ISO 9001:2015 certification for its Redwood City headquarters, recognizing its commitment to quality assurance across all operations, including R&D, manufacturing, and customer service. This certification validates the company's robust quality management system and its dedication to continuous improvement to deliver high-quality enzymatic solutions for therapeutics manufacturing. The company highlighted that this achievement reflects a collective commitment to excellence by all its employees.
Codexis (CDXS) Achieves ISO 9001:2015 Certification
Codexis Inc (CDXS) has successfully attained ISO 9001:2015 certification, demonstrating its commitment to quality assurance across all operations, from R&D to customer service, for its enzymatic solutions in therapeutics manufacturing. Despite this achievement, the company faces significant financial challenges including negative operating and net margins, declining revenue growth, and a high debt-to-equity ratio, leading to a precarious Altman Z-Score. While the company exhibits strong liquidity, market sentiment and analyst recommendations suggest caution, highlighting risks associated with its financial health and stock volatility.
Codexis Inc. Achieves ISO 9001:2015 Certification for Quality Management Excellence
Codexis Inc. has achieved ISO 9001:2015 certification, demonstrating its commitment to high-quality manufacturing practices across research, product development, and customer service. This certification reinforces the company's dedication to quality assurance and operational excellence, particularly for its enzymatic solutions used in therapeutics manufacturing. The company also reported Q3 2025 revenues of $8.6M, a decrease from the prior year, and recent insider selling activity.
Codexis Inc. Achieves ISO 9001:2015 Certification for Quality Management Excellence
Codexis Inc. has achieved ISO 9001:2015 certification, demonstrating its commitment to high-quality manufacturing practices across its processes, including research, development, and customer service. This certification applies to the company's Redwood City headquarters and its facilities, reinforcing its dedication to quality assurance and continuous improvement. CEO Alison Moore stated that this milestone reflects the company's efforts to provide excellent customer service and maintain operational excellence in its enzymatic solutions for therapeutics manufacturing.
What Codexis’ new ISO 9001 status means for enzyme buyers
Codexis Inc. announced it achieved ISO 9001:2015 certification on February 10, 2026, for its Redwood City headquarters, R&D labs, and non-GMP manufacturing facility. This certification signifies the company's commitment to quality management in the design, development, manufacturing, delivery, and support of its biomanufacturing products and services. The market reacted positively to the news, with Codexis stock (CDXS) gaining 5.59%.
Biofuel Enzymes Market Set to Soar: Innovations Driving Cleaner, Efficient Energy Solutions by 2032 | Major Companies - AB Enzymes GmbH, Codexis Inc., Logen Corporation, Royal DSM NV.
The Global Biofuel Enzymes Market is projected to grow at a CAGR of 6.4% during 2024-2031, driven by increasing demand for renewable fuels, technological advancements, and environmental regulations. Recent developments in the US and Japan highlight significant investments and innovations in enzyme technology to improve biofuel efficiency and cost-effectiveness. Key players in this market include AB Enzymes GmbH, Codexis Inc., and Royal DSM NV, among others.
